Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REX-001 in critical limb ischaemia with ischaemic ulcers in diabetic patients (Rutherford 5)
2016-003980-21Phase 3Completed
- Sponsor
- Ixaka
- Start
- Oct 2016
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic limb-threatening ischemia (CLTI), arterial ulcer and type 2 diabetes mellitus (T2DM) comparing REX-001 intra-arterial with Placebo intra-arterial (2 arms). Primary endpoint: Primary efficacy and safety endpoints. Started Oct 2016; status: completed.
02
Drugs
rexmyelocel-T
03
Conditions
chronic limb-threatening ischemia (CLTI)arterial ulcertype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-003980-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003980-21.